The Concrete Industry's Climate Change Problem And How AI Could Solve It
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Is Quantum Computing Inc. Stock a Buy After Earnings?
Key Points Technology investors have become intrigued by the potential of the quantum era as the artificial intelligence (AI) revolution unfolds. Quantum Computing, or QCi, is exploring photonic qubits -- a technology that's garnered the interest of academic research institutions and government agencies. While QCi looks promising to the casual viewer, savvy investors understand the bigger issues surrounding the company's popularity. 10 stocks we like better than Quantum Computing › Over the last three years, some of the biggest gains from the artificial intelligence (AI) megatrend have centered on semiconductors, data centers, cloud computing infrastructure, and enterprise software. But like all maturing themes, investors are craving a new wave of opportunity. Enter quantum computing, an emerging technology that is projected to have over $1 trillion in economic value by next decade, according to global management consulting firm McKinsey & Company. Unlike traditional AI applications, investors seem infatuated with speculative opportunities when it comes to investing in quantum computing stocks. Rather than traditional power players such as Nvidia, Alphabet, Microsoft, or Amazon, one of the most talked-about names in the quantum era is Quantum Computing Inc. (NASDAQ: QUBT), or QCi for short. Quantum Computing (the company) just reported earnings for the second calendar quarter of 2025 -- and let me tell you, there is a lot to unpack. Is Quantum Computing stock a buy after its Q2 report? Analyzing Quantum Computing's business results QCi's second-quarter earnings report highlighted several updates -- including mentions of a partnership with NASA, its addition to the Russell 2000 index, and incremental progress on its photonic qubit technology. While these details make for exciting headline content, how have they translated into measurable business results? In Q2, the company generated just $61,000 in sales while posting a net loss of $36.5 million. In other words, QCi essentially remains a pre-revenue business with no proven path to a turnaround or sustained positive unit economics. Distinguishing narrative from reality While quantum computing (the technology) is increasingly hailed as the next frontier of AI, prudent investors should remain cautious. At present, the field is still dominated by research and development (R&D) rather than practical utility. Quantum Computing (the company) is not signing Fortune 500 clients at a record pace because of any groundbreaking innovations it has achieved -- far from it. Frankly, I see QCi more as a hype-driven branding story -- perhaps deliberately spinning an exciting narrative while the core business fundamentals tell a very different story. Is Quantum Computing stock a buy? With such minimal traction and mounting losses, Quantum Computing looks more aspirational than investable -- focused on conceptual breakthroughs rather than tangible applications adopted by enterprise customers at scale. Where bullish investors might push back is on the company's balance sheet. Despite QCi's tiny revenue base and recurring burn, the company ended Q2 with $349 million of cash and equivalents. Investors should not be fooled by this. Quantum Computing's balance sheet strength comes from stock issuances as opposed to organic cash generation. This brings up the heart of the bear storyline: valuation. As of market close on Aug. 15, QCi boasted a market cap of $2.4 billion -- equating to a price-to-sales (P/S) multiple of more than 7,000. For perspective, this is orders of magnitude higher than established AI leaders with proven disruption. I think it's clear that Quantum Computing's management understands the disconnect between the company's valuation and business fundamentals. Issuing shares during a frothy stock market environment suggests that the company is capitalizing on enthusiasm driven largely by speculation and unsuspecting buyers before a valuation reset could -- and likely will -- occur. The key takeaway here is that QCi stock may look like a bargain for "just $15" per share, but smart investors understand that the absolute share price does not solely determine the value of a business. Quantum Computing (the company) is historically pricey and trading at levels reminiscent of the stock market bubble of the late 1990s driven by euphoria around the internet. With nearly no revenue, widening losses, and a dependence on equity raises, I think QCi is facing a looming liquidity crunch. At best, QCi is a moonshot gamble. Unless you are an investor comfortable with extreme volatility and abnormally outsize risk, Quantum Computing stock is best avoided for the time being. Should you invest $1,000 in Quantum Computing right now? Before you buy stock in Quantum Computing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Quantum Computing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Adam Spatacco has positions in Alphabet, Amazon, Microsoft, and Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, International Business Machines, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Is Quantum Computing Inc. Stock a Buy After Earnings? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
AITX Highlights AI-Driven Software Development Efficiencies and Near-Term ROAMEO Deployments
Company Reports Operational Efficiencies in Software Development and Progress on ROAMEO, SARA, and RIO Initiatives Detroit, Michigan--(Newsfile Corp. - August 18, 2025) - Artificial Intelligence Technology Solutions, Inc. (OTCID: AITX) (the Company), today provided an update on recent developments in its software operations and product deployment activities. To view an enhanced version of this graphic, please visit: Steve Reinharz, CEO, CTO and founder of AITX, shared in his weekly update that AI programming tools have irrevocably changed the Company's software development operations. "Software development has irrevocably changed. It has irrevocably changed over the last few months with AI building tools. This allows us to produce more and better code with many, many, many fewer people. And this is going to continue to accelerate over the next few months. And really, my expectation in the next 6 to 12 months is that all of our code is housed in an AI software program, and we're literally just asking this software to improve itself, or we're saying, add this feature." Alongside these operational efficiencies, AITX's RAD ROAMEO™ autonomous mobile security vehicles are moving toward initial client deployments. The Company is transitioning production from its Waterloo, Ontario R&D facility to Detroit to support expanded manufacturing capacity. "Very excited about the initial deployments, very excited about potential publicity that will get out of those deployments. Very excited about the profile of some of those clients. So, keep your eye on ROAMEO. Keep your eye on SARA™. Those are a large part of our concentration right now, because we feel that we could be the incumbent in that space moving forward," added Reinharz. AITX is also progressing its SARA (Speaking Autonomous Responsive Agent) agentic AI platform, positioning it as a market leader in AI-driven autonomous security, while new developments for the RIO™ (ROSA Independent Observatory) solution are in progress. The Company anticipates continued press coverage and further disclosures in the weeks ahead as these initiatives mature. AITX, through its primary subsidiary, Robotic Assistance Devices, Inc. (RAD), is redefining the nearly $50 billion (US) security and guarding services industry1 through its broad lineup of innovative, AI-driven Solutions-as-a-Service business model. RAD solutions are specifically designed to provide cost savings to businesses of between 35%-80% when compared to the industry's existing and costly manned security guarding and monitoring model. RAD delivers these tremendous cost savings via a suite of stationary and mobile robotic solutions that complement, and at times, directly replace the need for human personnel in environments better suited for machines. All RAD technologies, AI-based analytics and software platforms are developed in-house. The Company's operations and internal controls have been validated through successful completion of its SOC 2 Type 2 audit, reinforcing the Company's credibility with enterprise and government clients who require strict data protection and security compliance. RAD has a prospective sales pipeline of over 35 Fortune 500 companies and numerous other client opportunities. RAD expects to continue to attract new business as it converts its existing sales opportunities into deployed clients generating a recurring revenue stream. Each Fortune 500 client has the potential of making numerous reorders over time. About Artificial Intelligence Technology Solutions (AITX) AITX is an innovator in the delivery of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges and fuel new business ideas. Through its next-generation robotic product offerings, AITX's RAD, RAD-R, RAD-M and RAD-G companies help organizations streamline operations, increase ROI, and strengthen business. AITX technology improves the simplicity and economics of patrolling and guard services and allows experienced personnel to focus on more strategic tasks. Customers augment the capabilities of existing staff and gain higher levels of situational awareness, all at drastically reduced cost. AITX solutions are well suited for use in multiple industries such as enterprises, government, transportation, critical infrastructure, education, and healthcare. To learn more, visit and or follow Steve Reinharz on X @SteveReinharz. CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Artificial Intelligence Technology Solutions, Inc. (the "Company"). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price. ### Doug Clemons248-270-8273doug.c@ 1 To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Unlocking Oncology Pipelines with Next-Gen AI and Functional Data, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how to harness integrated functional multi-omics to enhance translational confidence and de-risk early-stage drug development for oncology programs. The featured speaker will discuss how to leverage key applications of AI and machine learning for extracting novel, actionable insights from complex multi-omic tumor datasets. Attendees will learn pragmatic, strategic approaches to integrate multi-omic and AI approaches into their own R&D pipelines for enhanced target identification and validation. The featured speaker will discuss the critical role of functional multi-omic data in overcoming current bottlenecks in oncology drug target discovery and development. TORONTO, Aug. 18, 2025 /PRNewswire/ -- How can functional multi-omic tumor data enable AI-driven target discovery and translational confidence? For pharma R&D and data science leaders, the demand for precise translational decisions has never been higher. However, the datasets currently available frequently fall short; they're fragmented, lack the necessary depth or don't accurately reflect real patient biology. This fundamental shortage of integrated, functional and clinically relevant data creates a significant bottleneck, impacting everything from the efficacy of internal AI models to the reliability of biomarker hypotheses. In this case-driven webinar, the featured speaker shares how a multi-disciplinary team harnessed a deeply profiled, functionalized tumor dataset to uncover and validate a novel oncology target: Vacuolar Protein Sorting–associated protein 4 (VPS4A/B). The discovery process began with a gene knockdown screen performed in 3D ex vivo cultures derived from clinically annotated patient-derived xenograft (PDX) tumors. Functional outcomes were integrated with deep transcriptomic data to train a machine learning model that accurately predicted VPS4 sensitivity. This approach led to the identification of CHAMP-002, a chemotype that triggered potent immunogenic responses and showed efficacy across multiple tumor types, including in combination with PD-1 blockade. This webinar will outline a framework for integrating deep tumor data into translational workflows that incorporate: AI/ML-ready datasets that are exportable, structured and grounded in fundamental tumor biology Integrated multi-modal layers, clinical history, omics, phenotypic data and drug response, all within a single, coherent system Data that maps to real-world patient cohorts, not abstract in vitro models Translational alignment for internal decision-making, target selection, biomarker validation and early development strategy Teams struggling with limitations with public datasets, failed to reproduce internal models or are looking to advance precision oncology initiatives, this webinar offers a window into how functionalized tumor data can drive more innovative R&D. Register for this webinar to learn how functional multi-omic data and AI integration can accelerate cancer target discovery. Join Michael Ritchie, PhD, MBA, Chief Commercial Officer, Champions Oncology, for the live webinar on Wednesday, September 3, 2025, at 11am EDT (4pm BST/UK). For more information, or to register for this event, visit Unlocking Oncology Pipelines with Next-Gen AI and Functional Data. ABOUT XTALKS Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit information about hosting a webinar visit Contact:Vera KovacevicTel: +1 (416) 977-6555 x371Email: vkovacevic@ View original content to download multimedia: SOURCE Xtalks
